Inflammation in Hypertension: Current Therapeutic Approaches

Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, George Latsios, Gerasimos Siasos, Costas Tsioufis, Anastasios Giolis, Christodoulos Stefanadis

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 37 , 2011

Become EABM
Become Reviewer


The role of inflammation as crucial underlying process contributing to the initiation and the progression of atherosclerosis as well as its clinical manifestations is well established. Recent data have demonstrated also a strong association between essential hypertension and inflammatory process. In addition, several studies have shown that tissue expression and plasma concentrations of several inflammatory biomarkers/mediators are related to increased risk of hypertension. The determination of markers such as acute phase proteins (C-reactive protein), adhesion molecules such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines is crucial in determining therapeutic responses and clinical outcomes of hypertensive patients. In addition, several therapeutic approaches targeting blood pressure may have also beneficial effects in terms of inflammation and thus further clinical benefits. Although the available data are encouraging, further large scale studies are required to evaluate the reported anti-inflammatory effects in management and treatment of arterial hypertension.

Keywords: Hypertension, inflammation, therapy, cytokines, blood pressure, atherosclerosis, cell infiltration, chemokines, Nuclear Factor-kappa B

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [4121 - 4131]
Pages: 11
DOI: 10.2174/138161211798764753
Price: $65

Article Metrics

PDF: 20